Statement: All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time.
Primary_evidence: INTERVENTION 1:    Arm A: Triptorelin + Letrozol   Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles   Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)   Letrozole: Letrozole 2.5 mg orally every day for 6 cycles INTERVENTION 2:    Arm B: Degarelix + Letrozol   Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles   Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)   Letrozole: Letrozole 2.5 mg orally every day for 6 cycles
Secondary_evidence: INTERVENTION 1:    Zoledronic Acid Upfront   Participants in the upfront arm received Zoledronic Acid 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence)or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.   Letrozole : Participants received 2.5 mg daily.   Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months. INTERVENTION 2:    Zoledronic Acid Delayed-start   In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronic acid 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.   Letrozole : Participants received 2.5 mg daily.   Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months.